Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Prostate Cancer Drug Developers Win Royal Society of Chemistry Award
A team of scientists at the ICR has won a prestigious Royal Society of Chemistry (RSC) award for the discovery and clinical development of prostate cancer drug abiraterone.
A new way to treat prostate cancer: The story of abiraterone
Abiraterone was designed and developed at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. First synthesised in the early 1990s, this year it completed the journey from an idea to life-extending treatment for men with advanced prostate cancer. The US Food and Drug administration (FDA) approved the use of abiraterone in men with castration resistant prostate cancer in April 2011, and European approval followed in September 2011.
Testing new radiotherapy techniques for breast cancer
Radiotherapy is one of the key treatments for cancer. More than 120,000 cancer patients in the UK are treated with radiotherapy each year and it continues to cure more people than all existing drugs combined. The Institute of Cancer Research founded its department of radiotherapy in the early 1940s and has been at the forefront of a number of important developments that have improved patient care.
New Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives, Study Finds
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.
New type of hormone therapy extends prostate cancer patients’ lives
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.
World’s Biggest Medical Imaging Microchip Heralds Better Treatment for Cancer Patients
A collaboration between scientists at four UK organisations including The Institute of Cancer Research (ICR) has created the world’s biggest microchip designed for medical imaging.
‘Like Finding Gold in Trafalgar Square’: Gene Breakthrough
In a surprise finding, three new breast cancer genes have been discovered next to the oestrogen receptor gene, which has been intensively studied by scientists for decades
Prostate Cancer Patients to Benefit from Drug Discovered at the ICR
A drug discovered at the ICR has today been approved in the US for use by men with metastatic prostate cancer.
Genetics are Key to Age at Which Girls Start their Periods
Genetic makeup explains more than half of the variation between UK women’s ages at first period, according to a study of almost 26,000 UK women published today.
First Patients To Receive New Cancer Drug AZD5363
An experimental drug the ICR helped discover has started Phase I safety testing in a range of cancer types.
Blood Test Shows Potential to Predict Treatment Response
Scientists at the ICR have shown evidence that a blood test can quickly identify patients who are responding to a new type of personalised cancer treatment.
New Radiotherapy Technique May Save More Healthy Breast Tissue
A new study will confirm whether an advanced radiotherapy technique that uses imaging of titanium clips implanted during surgery can reduce side-effects from breast cancer treatment.